Fiche centre
Universitatsklinikum Essen
Essen — Germany
Essais liés13clinical trials
VilleEssenlocalisation
PaysGermanylocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04774159
Essais cliniques associés
13| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Pleneva TM BGC20-0134 | SEP | Phase 2 | NCT01037907 | A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) | TERMINATED |
| Finerenone (Kerendia, BAY94-8862) | Maladie rénale chronique | Phase 3 | NCT05196035 | FIONA — A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | ACTIVE_NOT_RECRUITING |
| Edoxaban | Accident vasculaire cérébral | Phase 4 | NCT03950076 | EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF) | COMPLETED |
| Colchicine 0.5 MG Oral Tablet | Maladie coronarienne | Phase 3 | NCT04774159 | LEADER-PAD — Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk | RECRUITING |
| Inavolisib | Cancer | Phase 3 | NCT06790693 | INAVO123 — A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer | RECRUITING |
| Efgartigimod PH20 SC | Myasthénie | Phase 2/3 | NCT06392386 | ADAPT Jr SC — A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis | RECRUITING |
| PF-06939926 | Myopathies | Phase 3 | NCT04281485 | Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING |
| delandistrogene moxeparvovec | Myopathies | Phase 2 | NCT06128564 | ENVOL — A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD) | ACTIVE_NOT_RECRUITING |
| Efgartigimod IV or Efgartigimod PH20 SC | Myasthénie | Phase 2/3 | NCT05374590 | ADAPT Jr + — Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION |
| MEDI0618 | Migraine | Phase 2 | NCT06602479 | AURORA — A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine | ACTIVE_NOT_RECRUITING |
| Relief — Peripheral Nerve Stimulation Registry for Intractable Migraine Headache | Migraine | À vérifier | NCT02227758 | Relief — Peripheral Nerve Stimulation Registry for Intractable Migraine Headache | COMPLETED |
| Efgartigimod IV | Myasthénie | Phase 2/3 | NCT04833894 | ADAPT Jr — Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Casimersen | Myopathies | Phase 3 | NCT03532542 | An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy | TERMINATED |